FAQ booster shot
FAQ booster shot
What is a booster shot?
Once you have completed your basic immunisation (two shots of BioNTech-Pfizer, Moderna or AstraZeneca, a single shot of Johnson & Johnson, or a single dose of any of these four vaccines following a recovery from Covid-19), the Austrian Vaccination Committee recommends one additional dose to ensure long-term immunity. This is referred to as a booster - a dose that “boosts” the efficacy of the vaccine.
Where on the pre-booking platform should I indicate that I require a booster?
Under "Impfdaten” (vaccination data), you may choose whether you require a first dose or a booster dose.
Do I have to state when I received the vaccine and which vaccine it was?
Yes. Selecting a booster shot under "Impfdaten” will open up two additional input fields. In the first one, you need to enter the date when you completed your basic immunisation. This is the day you received your second dose of BioNTech-Pfizer, Moderna or Astra Zeneca, or your single dose of Johnson & Johnson. In the second field, you need to enter the vaccine your received.
I have recovered from Covid-19 and received a single dose. What should I put down?
You need to enter the date when you received your vaccination under "Datum der vollständigen Immunisierung” (date when immunisation was completed) and to enter the name of the vaccine in the field below.
Who is eligible for pre-booking a booster shot?
Anyone who is resident in Austria may pre-book a booster shot.
Please bear the following recommendations in mind:
1. Persons who received a single dose of the Janssen Covid-19 vaccine should receive a further dose after at least 28 days from the first dose (off-label), preferably using an mRNA vaccine. However, it is also possible to use another dose of the Janssen Covid-19 vaccine. Whether an additional dose will be required at a later point depends on the available data and epidemiological situation and will be decided in due time.
2. It is recommended that the following risk groups receive an additional dose within 6 to 9 months after completing their basic immunisation (off-label).
• Residents of senior citizens homes, nursing homes and care homes
• Persons aged 65 and older
• Persons who received 2 doses of Vaxzevria
• Persons from the age of 12 with pre-existing conditions and risks as outlined in the following:
Persons at risk of a severe case of Covid-19:
• Persons with Down syndrome
• Persons with dementia, intellectual or physical impairments (both in and outside care institutions); persons with physical disabilities with an increased risk of a severe case of Covid-19
• Adipose persons (BMI ≥30)
• Persons with functional or structural lung diseases requiring daily medication, for instance COPD, bronchial asthma, cystic fibrosis etc.
• Persons with functional or structural heart disease requiring daily medication, for instance atrial fibrillation, cardiac insufficiency, coronary heart disease, arterial hypertonia etc.
• Persons suffering from cancer
• Persons with immune deficiency or diseases requiring treatment with long-term and significant immunosuppressants, for instance cyclosporin, tacrolimus, mycophenolate, azathioprine, methotrexate, tyrosine kinase inhibitors, ongoing biologic therapy for a non-oncological diagnosis, or recipients of a bone marrow transplant within the last 2 years.
• Persons who received an organ transplant within the last year or are scheduled to receive an organ transplant (i.e. persons on the waiting list), or persons with graft vs host disease
• Persons with an HIV infection
• Persons with chronic kidney diseases and impaired renal function
• Persons with chronic liver disease and impaired liver function
• Persons with diabetes mellitus
• Persons with cerebral-vascular diseases/apoplexy and other chronic neurological diseases
• Persons with chronic inflammatory bowel diseases, auto-immune diseases and rheumatic diseases
• Persons with psychiatric diseases (e.g. bipolar disorder, schizophrenia, severe depression)
• Persons with diseases with functional or physical impairments that suggest a similarly severe case of Covid-19 as the diseases and symptoms listed here
3. The following persons may be offered a booster dose (off-label) from six months after their basic immunisation and should be offered a booster dose from 9 to 12 months after completing their basic immunisation:
• Staff working in senior citizens’ homes, nursing homes and care homes
• Healthcare staff
• Staff working in mobile care and support services, nursing and 24-hour care staff as well as caregivers within families
• Staff in educational facilities (childcare services, schools, universities etc.)
All other persons from age of 16 should be offered a booster dose (off-label) from 9 to 12 months after completing their basic immunisation.
5. Recovered persons who received a single dose of the vaccine should be treated as fully vaccinated persons as outlined in 2, 3 and 4. Recovered persons who have already received 2 doses (recovered plus 2 doses of the vaccine) do not require a Covid-19 booster shot for the time being.
Persons who recovered from a breakthrough infection after being vaccinated (symptomatic SARS-CoV-2 infection) or an infection after a complete first vaccination sequence do not require a booster shot for the time being. Persons who belong to a risk group or are chronically ill should have an antibody test one month after their recovery at the earliest.